On 20 April 2026, Swiss biomanufacturer Planetary announced a CHF 22 million ($28 million) raise: CHF 16 million ($20 million) of Series A equity, led by Radikal Capital and Oetker Ventures, plus CHF 6 million ($7.5 million) of credit financing. One outlet covering the same announcement, on the same day, ran the headline “Planetary Raises CHF 16 Million” — naming only the equity tranche.

That is not a second, smaller round. It is the same press cycle, and the body text of that article discloses the CHF 6 million credit facility two sentences later. The instrument split was reported correctly everywhere we checked; only one headline compressed a blended raise into its equity half. It is a minor case of a pattern this publication has documented before, where a summed headline obscures the risk capital actually committed — here running in the opposite direction, a headline that undercounts by naming only one piece of an accurately reported whole.

The instrument split is worth taking seriously in its own right, because it is not an accident. Planetary’s cofounder and CEO, David Brandes, told AgFunderNews in January 2026 — three months before this round closed — that the company had “financed the entirety of its current industrial production installations accessing non-dilutive debt instruments.” Debt at home, equity for the raise, and, for the company’s international expansion, neither: Planetary’s growth outside Switzerland runs through technology licensing to partners who supply their own capital. The clearest test case is a proposed collaboration with Dhampur Bio Organics (DBO), a publicly listed Indian sugar company, to produce mycoprotein “at below $1/kilo” — a number with real strategic logic behind it and, as of this writing, no disclosed capacity, cost breakdown, investment figure or timeline attached to it, in trade press or in DBO’s own stock-exchange filing.

The round, reconciled

Every figure below is from a source we fetched directly.

Component Amount
Series A equity CHF 16m ($20m)
Credit facility CHF 6m ($7.5m)
This round, total CHF 22m (~$28m)
Lead investors Radikal Capital, Oetker Ventures
Other named investors Royal Cosun, arc investors, Green Generation Fund, AgriFoodTech Venture Alliance, Astanor Ventures (existing), XAnge (existing)

Nine outlets — AgFunderNews, GGBA, vegconomist, Swiss Food & Nutrition Valley, Protein Production Technology International, EU-Startups, World Bio Market Insights, Green Queen and startupticker.ch — all reported the CHF 16m/CHF 6m split and the CHF 22m total on or around 20 April 2026. BioAlps’ headline names only the equity figure, but its own article body states plainly: “a CHF 16 million Series A funding round, complemented by CHF 6 million in credit.” There is no separate CHF 16 million raise. It is the same announcement, read carelessly into a headline by one outlet and correctly by everyone else, including BioAlps’ own reporter.

Practical consequence: when a headline names a single figure for a company you know has raised blended instruments before, check whether that figure is the whole round or one tranche of it before using it in a comp table. Here the answer took one extra fetch to settle. It will not always.

What “total funding to date” actually adds up to

Reported lifetime totals for Planetary cluster loosely around $40 million (roughly CHF 32–34 million), but the sources are not identical in what they count. Asked directly about funding history in the January 2026 AgFunderNews interview, Brandes gave a specific list: “In addition to undisclosed funding, public records include a CHF 7.5 million ($9.8 million) seed round, a CHF 3 million ($3.9 million) strategic investment from Cosun, and a CHF 1.8 million ($2.3 million) grant from Innosuisse.” Add the April round:

Instrument Amount (CHF)
Seed round 7.5m
Cosun strategic investment 3.0m
Innosuisse grant 1.8m
April 2026 Series A + credit 22.0m
Sum of disclosed components 34.3m

That sum lines up with vegconomist’s and PPTI’s reporting of “nearly CHF 34 million” and roughly $40 million. GGBA’s figure of “approximately CHF 32 million” is close but not identical — plausibly a rounding difference, or an exclusion of the Innosuisse grant, which is a government award rather than investment capital and arguably does not belong in a “funding raised” total at all. Neither outlet states its methodology, so we cannot resolve which treatment is correct; we can only show the arithmetic and flag that the two published totals do not simply nest inside one another.

The more important sentence in Brandes’s own quote is its opening clause: “in addition to undisclosed funding.” By the company’s own account, the CHF 34.3 million of itemised instruments is a floor, not a total. How much sits above it has not been stated anywhere we could find.

Two capital structures for two kinds of scale

Set the debt-financed Swiss plant beside the licensed Indian proposal and a consistent shape emerges — one this publication has already mapped in detail for the wider mycoprotein-siting question in our analysis of co-located mycoprotein capacity, which covers Planetary’s Aarberg plant, ENOUGH and Enifer side by side. This piece narrows in on financing rather than siting, but the two are related: co-location is what makes both capital strategies possible.

At home, in Aarberg: Planetary built its own commercial mycoprotein facility, co-located with a Schweizer Zucker sugar mill, and financed the industrial installations entirely with debt. Debt does not dilute existing shareholders, but it is still Planetary’s liability — if margins do not materialise, a lender’s claim on the company’s assets does not disappear the way an underwater equity stake does. “Non-dilutive” is not the same as “risk-free.” It is a choice about which stakeholders absorb the downside, made possible because the plant sits inside an existing industrial site with existing utilities, which is the kind of collateral a lender can underwrite.

Abroad, in the proposed Indian venture: Planetary is not proposing to build or own anything. Under the framework described to AgFunderNews, DBO would license Planetary’s BioBlocks platform and install mycoprotein production capacity at its own sugarcane processing site. DBO supplies the land, the utilities, the effluent infrastructure and — critically — the capital. Planetary supplies the technology and, presumably, earns a licensing fee or royalty rather than carrying a plant on its own balance sheet.

Practical consequence: these are not two examples of the same discipline. Debt still leaves Planetary exposed to its own project’s economics. Licensing does not — the capital risk, and with it the execution risk of ever producing mycoprotein below $1/kg, sits with DBO’s balance sheet, not Planetary’s. That is a materially lower-risk position for Planetary specifically, and it is worth naming as exactly that rather than folding it into a single “capital discipline” story.

What is actually signed in India, and when

The timeline matters and is worth being precise about, because the sequence undercuts any assumption that the April fundraise is what capitalises the Indian venture.

Date Event
22 January 2026 DBO’s board approves Q3 FY26 results and discloses, per SEBI listing regulations, “the execution of a non-binding term sheet with Switzerland-based Planetary SA”
27–30 January 2026 Trade press (AgFunderNews, PPTI, World Bio Market Insights, Plant Based News, Green Queen, Nutrition & Food Spectrum India) covers the exploratory collaboration and the sub-$1/kg target
20 April 2026 Planetary announces the CHF 22 million Swiss round — three months later, and not described by any source as earmarked for India

The India collaboration was a non-binding term sheet before Planetary’s own fundraise closed. No source ties proceeds of the April round to the Indian project. If capital ever flows into an Indian facility, the sourcing evidence we have points to it coming overwhelmingly from DBO, not from Planetary’s balance sheet — consistent with the licensing structure described above.

DBO’s own disclosure, filed under SEBI listing regulations and syndicated by TipRanks, is the most formal document either company has produced about this collaboration, and it contains zero figures: no investment amount, no capacity, no capital expenditure, no timeline. Its full description of the deal: “a non-binding term sheet with Switzerland-based Planetary SA to explore an exclusive arrangement for producing and commercializing mycoprotein in India using sugar and side streams as feedstock… subject to definitive agreements and regulatory disclosures.” That is the entire quantitative content of a stock-exchange filing from a company legally obligated to disclose material terms once they exist. They do not yet exist, or DBO has not yet been required to disclose them.

The $1/kg claim has no published denominator

The AgFunderNews interview that broke the India story asked Brandes directly what the $1/kg figure rested on. His answer named three qualitative factors and no numbers: “Sugar side streams are abundant, labor costs remain low, and energy can be integrated with sugar mills.” Asked about capacity or timeline, he said the company “cannot comment… however we see Planetary’s mycoprotein as serving both the meat alternative, hybrid meat, as well as dairy alternatives and supplements markets at the lowest possible price points.” In a separate interview with Protein Production Technology International, Brandes went further, asserting the figure “is not based on assumptions, but rather on firsthand production data” from the Aarberg facility. That is a claim about the number’s provenance, not a disclosure of the number’s components — no cost breakdown, no published Aarberg production cost, no stated capacity for the Indian facility that the $1/kg figure would scale to.

We have written about this exact shape of claim before: a precise-sounding figure, offered with confidence, resting on a base that is never published. Our analysis of Paleo’s 613-fold cost-reduction claim made the general case that a ratio or a target without its underlying quantities constrains nothing — it can be consistent with wildly different businesses. Here the mechanism is slightly different: $1/kg is an absolute figure, not a ratio, so it does constrain the claim somewhat more than an unanchored multiple would. But it is still a target attached to a facility that does not exist yet, proposed by two companies that have between them disclosed no capital expenditure, no nameplate capacity and no construction timeline for the site that number depends on.

Our earlier reporting on mycoprotein capital intensity gives one useful anchor. Enifer, the only company in the category to have published both a capital cost and a capacity figure for a commercial plant, is building at roughly €11,000 per tonne of annual capacity — a figure that, on its own, implies something on the order of €0.55–1.10 per kilogram in capital charge alone, before a single input is paid for, depending on assumed asset life and utilisation (see our full working of that arithmetic). A sub-$1/kg all-in cost in India would require materially lower capital intensity than that Finnish benchmark, or a longer asset life, or — the explanation both Brandes and DBO’s Gautam Goel have pointed to — capital and utilities that already belong to the sugar mill, with only the marginal fermentation step counted. Which of those is actually doing the work is precisely what neither company has said.

Practical consequence: treat $1/kg as a target the deal’s structure was designed to make achievable on paper — by excluding land, utilities and effluent treatment from the boundary of what Planetary is capitalising — rather than as a verified all-in cost. The question worth asking either company directly is the one Brandes did not answer: what counts as a cost, and what counts as infrastructure DBO already owned.

A naming error worth noting

One outlet’s coverage of the same 28 January 2026 announcement — Green Queen’s follow-up piece — names the Indian partner as “DCM Shriram Bioseeds (DBO).” We checked the raw text of the article directly; the phrase appears exactly that way, twice. DCM Shriram is a real, large Indian conglomerate with an agricultural seed-genetics division called Shriram Bioseed. It is not the same company as Dhampur Bio Organics. Every other source in this piece — AgFunderNews, PPTI, World Bio Market Insights, Plant Based News, Nutrition & Food Spectrum India, and DBO’s own SEBI-governed stock exchange disclosure under ticker DBOL — names the partner as Dhampur Bio Organics, and Dhampur’s own leadership page confirms Gautam Goel, quoted in every version of this story, as its managing director. We are treating this as an editorial error in that one article rather than as a substantive fact in dispute, and are not citing it for the partner’s identity. It is a small, concrete example of why this publication checks a company name against a primary filing before repeating it, rather than trusting that a widely used abbreviation always points to the same entity trade press assumes.

The ALDI Suisse claim, and what it is actually a claim about

Planetary’s other headline number is commercial rather than financial: mycoprotein sold at “price parity with conventional chicken.” It is worth being precise about what was launched and who verified the comparison.

In July 2025, ALDI Suisse rolled out Planetary’s MyVay Gourmet Filet — 93% mycoprotein by weight, with egg white, sunflower oil and natural flavouring making up the rest — across 242 stores at CHF 4.99 per 210g pack, which is CHF 22.7 per kilogram. Brandes told Green Queen this “puts Planetary’s product at price parity with Aldi’s Swiss chicken filet.” That comparison is Brandes’s own statement; we found no source in which a journalist independently checked ALDI’s conventional chicken filet price against the mycoprotein product at the same date and confirmed the parity claim from ALDI’s own pricing data. The retail arithmetic on Planetary’s own product — CHF 4.99/210g to CHF 22.7/kg — is internally consistent and simple to verify. The comparison point is not.

It is also worth noting what was actually launched: a product containing egg white, not a vegan one. Reporting from January 2026 described a fully vegan version of the filet as expected in “spring” 2026; we found no fetched source confirming that launch occurred, so we are not claiming it did.

The counter-argument

The tidy version of this piece is that Planetary has built a capital-efficient structure — non-dilutive debt for what it owns, licensing for what it doesn’t — and that this genuinely lowers its own risk relative to a company self-funding every plant with equity. That case is real. Brandes made it explicitly to AgFunderNews when describing why contract manufacturing does not work for bulk fermented commodities but co-location licensing does: control without ownership of every asset.

But the same structure that lowers Planetary’s capital risk also means the industry’s most aggressive published cost claim for mycoprotein will be tested, if it is tested at all, using someone else’s capital and someone else’s execution. If the Indian facility is built and comes in above $1/kg, or is delayed years past any reasonable expectation, or the term sheet lapses without a definitive agreement — the kind of outcome non-binding term sheets produce often enough that it is not a remote scenario — Planetary’s downside is a forgone royalty stream and a quietly retired number, not a stranded asset on its own balance sheet. That asymmetry is the actual content of “reduced capital risk” here: it protects Planetary’s downside, not the credibility of the $1/kg figure the market has been repeating since January.

What we could not establish

  • The size of “undisclosed funding” Brandes referenced. His own account of Planetary’s funding history explicitly excludes an unspecified amount. We can only report the components he named.
  • Which treatment explains the CHF 32m vs. CHF 34m gap between GGBA’s and vegconomist/PPTI’s reported lifetime totals. Neither outlet states its methodology.
  • Any quantitative basis for the $1/kg target — no capacity, capital expenditure, cost breakdown or timeline has been published by either Planetary or DBO, including in DBO’s own SEBI-governed stock filing.
  • Whether a definitive agreement has since been signed. As of this writing, every source describes the DBO collaboration as a non-binding term sheet “subject to definitive agreements and regulatory approvals.” We found no fetched source reporting that those agreements have been finalised.
  • Whether ALDI’s conventional chicken filet price was independently confirmed against Planetary’s CHF 22.7/kg figure at the time of the parity claim, by anyone other than Planetary.
  • Whether the vegan version of the MyVay filet, reported as expected in spring 2026, has launched.

What to watch

  1. A definitive, signed agreement with DBO, and whether it comes with a disclosed capacity, capital expenditure figure or timeline — the single data point that would let this claim actually be checked.
  2. DBO’s subsequent quarterly disclosures. As a SEBI-listed company, any material progress on this term sheet is a disclosure obligation, not a press-release choice — which makes DBO’s own filings a better tracking mechanism than trade coverage going forward.
  3. Planetary’s promised second closing, described by Brandes in April as planned for “later this summer” 2026. We found no source confirming it closed; if and when it does, watch whether the equity-to-debt ratio holds or shifts.
  4. Whether Planetary ever publishes an Aarberg cost-per-kilogram figure. Brandes has twice pointed to “firsthand production data” from that plant as the basis for the India target without publishing the data itself. That single number would resolve most of the open questions in this piece.